As Head of China for the Lung Cancer Initiative (LCI) at Johnson & Johnson (J&J) and the World Without Disease Accelerator (WWDA), Silvia is responsible for leading the development and execution of the China portion of the LCI & WWDA strategy, which is critical to the groups’ comprehensive approach to prevent, intercept and cure disease.
With more than 20 years in industry, academia and government, Silvia has diverse experience in such areas as product development, portfolio management and product launches. She has a proven track record as a results-driven innovator, leader, and collaborator. Silvia joined the LCI in early 2019 as a leader of a critical priority program for the early detection and treatment of lung cancer. Before this, she served in leadership positions at Ethicon and LifeNet Health, Inc., and was also a Senior Scientist at the National Institutes of Health (NIH).
Silvia earned a Ph.D. and a Master of Science degree in Biomechanics and Mechanical Engineering from the University of Maryland and completed a postdoctoral fellowship in Tissue Engineering at the University of California, San Diego. She also earned an MBA from the Mason School of Business at the College of William and Mary, and earned her Bachelor of Science degree in Mechanical Engineering from the Shanghai University of Science and Technology. She has authored more than 50 peer-reviewed articles and patents/patent applications.